Medical Quiz

Immunology IBD Quiz


Preview:


NK cells and T cells are major components of the adaptive immunity

A. TRUE

B. FALSE


What were the treatment arms, and their duration, for the UNITI-1 and UNITI-2 induction studies?

A. Ustekinumab ~6 mg/kg or 130 mg, versus adalimumab over a 12-week period

B. Ustekinumab ~3 mg/kg or 220 mg versus vedolizumab over an 8-week period

C. Ustekinumab ~6 mg/kg or 130 mg, versus placebo over an 8-week period

D. Ustekinumab ~4 mg/kg versus adalimumab and placebo over a 12-week period


Which biologic consists of Human p75 TNF receptor

A. Secukinumab

B. Abatacept

C. Etanercept

D. Adalimumab


Which of the following phases of Immune Response is not achieved in IBD?

A. Cognitive phase

B. Activation phase

C. Effector phase

D. Normalization phase


Adalimumab is a humanized mab produced by phage display Technology

A. TRUE

B. FALSE


Etanercept is not indicated in IBD because it

A. inhibits non pathogenic IL17 required for mucosal integrity in IBD

B. inhibits only soluble TNF not membrane bound like in IBD

C. initiate paradoxical IBD manifestations


Stelara is approved for ASUC (Acute Severe UC) treatment

A. TRUE

B. FALSE


All of the below were in the inclusion criteria for UNIFI patients EXCEPT:

A. ≥18 years of age

B. Moderate-to-severe UC diagnosis ≥3 months before screening

C. Stable doses of 5-ASA and immunomodulators were maintained from induction BL through maintenance Week 44

D. Prior TNF-antagonist therapy was discontinued ≥8 weeks and vedolizumab ≥4 months before study entry; other conventional therapies were discontinued ≥2-4 weeks before study entry

E. Oral corticosteroids were maintained at a stable dose during induction and tapered upon entering maintenance


What is the Ustekinumab maintenance dose for a patient with CD weighing 100 kg?

A. 90 mg s.c.

B. 260 mg i.v.

C. 290 mg s.c.

D. 520 mg s.c.


How long is the duration of innate immunity action after infection?

A. 0 to 12 hours

B. 0 to 24 hours

C. 12 to 72 hours

D. 24 to 72 hours


IL17 is a regulatory cytokine with a major role in Ankylosing Spondylitis

A. TRUE

B. FALSE


What was the primary endpoint for both the UNITI-1 and UNITI-2 studies?

A. CDAI-70 response at Week 8

B. CDAI-90 response at Week 6 and clinical response at Week 6

C. Clinical response at Week 6

D. Clinical remission at Week 8


Which biologic inhibits signal transduction in T cells

A. Anti TNFs

B. IL12/23 inhibitor

C. JAK inhibitors

D. Anti integrins


Fc region in the Structure of an Antibody (IgG) is the variable domain specific to certain Ag

A. TRUE

B. FALSE


UST is inhibiting IL12 & IL23 due to its action on ………… subunit

A. p19

B. p40

C. p75


Vedolizumab is a fully human Ab that works on B cell activation

A. TRUE

B. FALSE


Tositumomab is a chimeric monoclonal Ab for inflammatory diseases

A. TRUE

B. FALSE


Which of the below subunits is specific to IL23

A. p19

B. p40

C. p75


Which of the following was NOT a key finding from the UNIFI induction study of Ustekinumab in UC?

A. Symptomatic improvement observed as early as Week 2

B. Clinical response in ~80% of patients at Week 16

C. CS-free remission in ~80% of patients at Week 24


What was the CDAI range of patients with Crohn’s disease in UNITI-1 and UNITI-2?

A. 300–450

B. 220–450

C. 150–350

D. 280–400


Total volume of Stelara iv induction dose is

A. 150 ml

B. 200 ml

C. 250 ml

D. 300 ml


What was the primary endpoint for the IM-UNITI study?

A. Clinical remission at Week 44

B. CDAI-70 response at Week 32

C. Clinical response at Week 44

D. CDAI score change of >100


What is the i.v. ustekinumab induction dose for a patient with CD weighing 86 kg?

A. 260 mg

B. 520 mg

C. 290 mg

D. 860 mg


What was the main objective of the IM-UNITI maintenance study?

A. To investigate the efficacy and safety of Ustekinumab 90 mg q8w or q12w versus placebo over a 44-week period

B. To investigate the efficacy and safety of Ustekinumab 130 mg q5w or q10w versus placebo over a 44-week period

C. To investigate the efficacy and safety of Ustekinumab 80 mg q12w versus adalimumab or placebo over a 44-week period

D. To investigate the efficacy and safety of Ustekinumab ~6 mg/kg or 130 mg versus placebo over a 48-week period




Disclaimer:

Medical Quiz should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional. All content on this website is for informational and educational purposes only.